Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies, which it says overcome several of the major challenges with current degradation platforms, including oral bioavailability and CNS exposure.
Founded in 2020 and based in Cambridge, UK, the company builds on work carried out in the Gunning Group at University of Toronto Mississauga in Canada. Prof. Patrick Gunning is Dunad’s co-founder, acting Chief Executive Officer and Chief Scientific Officer.
Dunad’s small molecule platform induces targeted degradation of disease-causing proteins via direct modulation of the target protein’s surface topology. The company says its novel molecular approach, based on mono-valent small molecules, is fully tuneable to be exquisitely selective for the target, and is underpinned by a target-class agnostic mechanism of action that is distinct from traditional mechanisms of targeted protein degradation. The company’s approach also makes for a more effective drug discovery and development path.
The company now plans to further build the platform, enhance its proteomics and bioinformatics infrastructure and expand its proprietary library of covalent degraders with the aim to advance a pipeline of novel therapeutics, predominantly focused on oncology and CNS indications.
Subscribe for alerts on new companies featured on Startups.Bio
BioTryp Therapeutics is University of Cambridge spin-out biotechnology company that focuses on the development of small molecules to inhibit biofilm formation, which causes 80% of …
Bastion Therapeutics is a pre-clinical stage biotechnology company focused on developing best-in-class Treg cell therapies, which can target the root causes of inflammatory disorders and …
HOVANA is a digital biology company tackling translational dysfunction as a driver of serious diseases. Leveraging insights into cellular reprogramming, HOVANA is inventing a new …
Founded in 2022, Couragene is a biotechnology company developing first-in-class in vivo genetic therapies using its proprietary delivery platforms. The company's technology holds potential for …
Function Oncology is a precision medicine company advancing a CRISPR-powered personalized functional genomics platform to understand cancer in unprecedented and patient-specific detail. By moving beyond …
Founded in 2023, Mallia Therapeutics is a biopharmaceutical company developing soluble CD83 (sCD83) for the treatment of hair loss. sCD83, which was discovered as an …